



## Tuberculosis Diagnostic, Treatments and Vaccines Research

Guest Editor:

**Dr. Machelart Arnaud**

Institut Pasteur de Lille, Centre  
d'Infection et d'Immunité de Lille,  
Université de Lille, CNRS  
UMR9017, INSERM U1019, CHU  
Lille, 59000 Lille, France

Deadline for manuscript  
submissions:

**closed (30 November 2023)**

### Message from the Guest Editor

BCG (*Bacillus Calmette-Guérin*) remains the only effective vaccine against tuberculosis. Its discovery early in the 20th century allowed a drastic reduction in children mortalities. However, the vaccine has been shown to provide variable protection in adults against pulmonary tuberculosis. Novel and more effective strategies, including new vaccines or different use of BCG, are now essential to reduce the prevalence of the disease and foresee its eradication.

TB diagnosis is particularly difficult in immuno-compromised individuals or children. In this regard, the latest WHO report highlights improvements in TB diagnostics and shortening the time to initiate appropriate treatment as key priorities.

For this Special Issue of *Vaccines*, we kindly invite authors to submit an original research article or a review focusing on the recent advances to diagnose, prevent or treat TB. Potential topics could include (but are not limited to): new treatment strategies, vaccine studies, or the setting up of a new diagnostic test.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)